StreetInsider.com News Articles

Biogen's Empaveli cuts proteinuria 75% in teens with rare kidney disease

Thu, 17 Sep 2026 16:15:16 -0400

Biogen Inc. (Nasdaq: BIIB) announced the publication of results from a prespecified adolescent subgroup analysis of its Phase 3 VALIANT study evaluating Empaveli (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology.

The analysis examined 55 adolescents aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). At Week 26, Empaveli-treated patients achieved a 75% relative reduction in proteinuria versus placebo (95% CI: 59%-84%; nominal p<0.001), with reductions observed as early as Week 4.

Additional results showed that 71% of Empaveli-treated adolescents achieved at least a 50% reduction in proteinuria, compared with 4% in

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-M

Thu, 17 Sep 2026 16:15:00 -0400

EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo
EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based on VALIANT study
Publication follows a recent FDA label update to expand EMPAVELI’s indication to include reducing the loss of kidney function in patients 12 years and older, in addition to reducing proteinuria

CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI® (pegcetacoplan)

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-M

Thu, 17 Sep 2026 16:15:00 -0400

EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo
EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based on VALIANT study
Publication follows a recent FDA label update to expand EMPAVELI’s indication to include reducing the loss of kidney function in patients 12 years and older, in addition to reducing proteinuria

Biogen (BIIB) Reiterated at Buy by Stifel After Investor Meeting

Thu, 10 Sep 2026 07:39:06 -0400

Stifel analyst Paul Matteis reiterated a Buy rating and $242.00 price target on Biogen (NASDAQ: BIIB).

The analyst commented, "We hosted an investor meeting with Biogen CEO Chris Viebacher, where management continues to feel confident in the company's positioning heading into multiple readouts from the immunology pipeline. On litifilimab, BIIB described how their experience in MS has helped them carefully design/recruit these ph3s in SLE/ CLE. BIIB believes Lupus represents a highly attractive commercial opportunity where litifilimab has multiple paths to differentiation, again with analogs to MS where the key is positioning the drug as the right/optimal agent for certain populations

Biogen (BIIB) PT Raised to $175 at HSBC

Thu, 10 Sep 2026 03:28:36 -0400

HSBC analyst Rajesh Kumar raised the price target on Biogen (NASDAQ: BIIB) to $175.00 (from $165.00) while maintaining a Reduce rating.

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach